Baoying Medical and Health Shanghai-Hong Kong-Shenzhen Equity Securities Investment Fund (abbreviation: Baoying Medical and Health Shanghai-Hong Kong-Shenzhen Stock C, code 020437) announced its latest net value on September 30, up 10.08%.
Baoying Medical & Health Shanghai-Hong Kong-Shenzhen Stock C was established on December 26, 2023, and the performance comparison benchmark is Shenyin & Wanguo Pharmaceutical and Biological Industry Index yield of ×70% + Hang Seng Composite Index yield ×20% + CSI Composite Bond Index yield ×10%. The fund has returned 1.09% since its inception, with a -1.07% return this year and a 13.57% return over the past month.
The fund manager is Yao Yi. Yao Yi has managed (or intends to manage) the fund since December 26, 2023, with a return of 1.09% during his tenure.
According to the latest periodic report, the fund's top 10 heavy stocks are as follows:
| stock symbol | ,stock name | ,position ratio | , number of shares held (shares). | Market value of the position (RMB). |
| 002422 | Kelun Pharmaceutical | 8.12% | 3471000 | 105 million |
| 000423 | Dong'e Ejiao | 7.88% | 1631900 | 102 million |
| 688076 | Nuotai Biotech | 7.23% | 1196881 | 93.6918 million |
| 000403 | Palin Biotech | 6.88%, | 3344800 | 89.1724 million |
| 688506 | Baili Tianheng | 6.58% | 470324 | 85.3168 million |
| 300705 | Jiudian Pharmaceutical | 6.54% | 3168120 | 84.7155 million |
| 300049 | Furui shares | 5.71% | 1469730 | 73.9862 million |
| 600129 | Taiji Group | 5.08% | 2275056 | 65.7946 million |
| 002653 | Haisco | 4.87% | 2057600 | 63.1683 |
| million 300573 | Xingqi eye medicine | 3.94% | 311140 | 51.027 million |
Ticker Name
Percentage Change
Inclusion Date
